BIOLASE Inc
NASDAQ:BIOL
Intrinsic Value
BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. [ Read More ]
The intrinsic value of one
BIOL
stock under the Base Case scenario is
2.763
USD.
Compared to the current market price of 0.148 USD,
BIOLASE Inc
is
Undervalued by 95%.
BIOLASE Inc's market capitalization is 4.9m USD.
BIOL stock price is 0.148 USD.
BIOL stock price (0.148 USD) is 95% less than its Intrinsic Value (2.763 USD).
BIOL stock price (0.148 USD) is 97% less than its Relative Value (5.457 USD). Open Relative Valuation
BIOL.
BIOL's Revenue has grown by 1% over the past 12 months.
BIOL has positive Net Debt. This means that the company has more debt (12m USD) than cash and short-term investments (7m USD).
BIOL's long-term assets (35m USD) exceed its long-term liabilties (33m USD).
BIOL's short-term assets (25m USD) exceed its short-term liabilties (20m USD).
BIOL has positive Gross Profit for the last twelve months.
BIOL's ROE (Return on Equity) has significantly decreased in the last 3 years from -218% to -1 099%, and is approaching profitability.
BIOL's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -101% to -71%, and is approaching profitability.
BIOL's Revenue has been growing by an exceptional 29% per year for the last 3 years.
BIOL has negative Operating Income for the last twelve months.
BIOL has negative Net Income for the last twelve months.
BIOL's ROE (Return on Equity) for the past 12 months is negative and is equal to -1 099%.
BIOL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -71%.
BIOL has negative Free Cash Flow for the last twelve months.
BIOL has negative three-year average ROE (Return on Equity): -249%. The company is not efficient at transforming stockholders' equity into net income.
BIOL has negative three-year average ROIC (Return on Invested Capital): -85%. The company is not efficient at using invested capital to generate operating income.
BIOL's D/E (Debt to Equity) is very high and is equal to 6.02.
BIOL's Altman Z-Score is very low and is equal to -12.29.
BIOL doesn't generate enough operating income (-18m USD) to safely cover interest payments on its debt (2m USD).
Fundamental Analysis
BIOLASE Inc
Balance Sheet Decomposition
BIOLASE Inc
| Current Assets | 24.9m |
| Cash & Short-Term Investments | 6.6m |
| Receivables | 5.5m |
| Other Current Assets | 12.8m |
| Non-Current Assets | 10.2m |
| PP&E | 7m |
| Intangibles | 2.9m |
| Other Non-Current Assets | 268k |
| Current Liabilities | 19.7m |
| Accounts Payable | 6.1m |
| Accrued Liabilities | 7.8m |
| Other Current Liabilities | 5.8m |
| Non-Current Liabilities | 13.5m |
| Long-Term Debt | 11.8m |
| Other Non-Current Liabilities | 1.7m |
Earnings Waterfall
BIOLASE Inc
|
Revenue
|
49.2m
USD
|
|
Cost of Revenue
|
-32.4m
USD
|
|
Gross Profit
|
16.7m
USD
|
|
Operating Expenses
|
-34.7m
USD
|
|
Operating Income
|
-17.9m
USD
|
|
Other Expenses
|
-19.7m
USD
|
|
Net Income
|
-37.6m
USD
|
Free Cash Flow Analysis
BIOLASE Inc
BIOL Profitability Score
Profitability Due Diligence
BIOLASE Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
BIOLASE Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
BIOL Solvency Score
Solvency Due Diligence
BIOLASE Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Score
BIOLASE Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOL Price Targets Summary
BIOLASE Inc
Ownership
BIOL Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BIOL Price
BIOLASE Inc
| Average Annual Return | -49.52% |
| Standard Deviation of Annual Returns | 39.66% |
| Max Drawdown | -100% |
| Market Capitalization | 4.9m USD |
| Shares Outstanding | 33 256 900 |
| Percentage of Shares Shorted | 7.06% |
Company Profile
BIOLASE Inc
Country
Industry
Market Cap
Dividend Yield
Description
BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. The company is headquartered in Foothill Ranch, California and currently employs 158 full-time employees. The firm develops, manufactures, markets and sells laser systems, which provides helps to dental practitioners and their patients. The Company’s systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons and other dental specialists to perform a range of dental procedures, including cosmetic, restorative and complex surgical applications. The company offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft tissue) systems. Its Waterlase brand uses a patented combination of water and laser energy and performs using drills, scalpels and other traditional dental instruments for cutting soft and hard tissue. The company offers its diode laser systems to perform soft tissue, pain therapy and cosmetic procedures, including teeth whitening. The company has approximately 301 issued and 38 pending United States and international patents.
You don't have any saved screeners yet
